COMBINATIONS OF BIOMARKERS FOR COLORECTAL TUMORS

摘要

1. A method comprising: (a) measuring in a sample obtained from a subject, the amount of each biomarker of a biomarker panel containing at least one high priority biomarker and at least two major biomarkers selected from the group consisting of IL1B, PTGS2, S100A8, LTF, CXCL10 and CACNB4; (b) calculating a probability estimate based on the measurement in step (a); and (c) excluding a colorectal tumor for a subject if the score in step (b) is lower than a predetermined score; or (d) confirmation of the likelihood of a colorectal tumor for a subject if the score in step (b) is higher than a predetermined score. 2. A method comprising: (a) measuring in a sample obtained from a subject, the amount of each biomarker of a biomarker panel containing at least one high priority biomarker and at least two major biomarkers selected from the group consisting of IL1B, PTGS2, S100A8, LTF, CXCL10 and CACNB4; (b) comparing the amount measured in step (a) with a reference value; and (c) classifying the subject as more likely to have a colorectal tumor when an increase or decrease in the amount of each biomarker of the biomarker panel relative to the reference value is detected in step (b). The method of claim 2, further comprising administering to a subject classified in step (c) a therapeutically effective amount of at least one colorectal modulating agent. The method of claim 1 or 2, wherein said at least one high priority biomarker is selected from the group consisting of S100A8, LTF, CXCL10 and CACNB4.5. The method of claim 1 or 2, wherein said at least one high priority biomarker is selected from the group consisting of S100A8, LTF, CXCL10, CACNB4, MMP9, CXCL11, EGR1, JUN, TNFSF13B, GATA2, ΜΜΡ11, ΝΜΕ1, PTGES, CCR1 , CXCR3, FXYD5, IL8, ITGA2, ITGB5, MAPK6, RHOC, BCL3, CD63, CES1, MAP2K3, MSL1 and PPARG. 6. The method of claim 1